Céline Louapre Profile
Céline Louapre

@clouapre

Followers
711
Following
247
Media
37
Statuses
371

Neurologue et chercheur @Sorbonne_Univ_ @MedecineSU @APHP @HopPitieSalpe @InstitutCerveau @ParisBrainInst spécialisée dans la #SEP #MS et autres pathol. inf.

Paris, France
Joined November 2016
Don't wanna be here? Send us removal request.
@clouapre
Céline Louapre
10 months
RT @ViolettaZujovic: 🚨 Cues of trained immunity in macrophages of Multiple Sclerosis patients. Curious to know more? 🔍.Dive into our late….
Tweet card summary image
neurology.org
Background and ObjectivesIn multiple sclerosis (MS), immune cells invade the CNS and destroy myelin. Macrophages contribute to demyelination and myelin repair, and their role in each process depends...
0
8
0
@clouapre
Céline Louapre
11 months
RT @DrWBRO: Fantastic few days in Copenhagen for #ECTRIMS2024 🧠
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
3
0
@grok
Grok
8 days
Join millions who have switched to Grok.
221
458
3K
@clouapre
Céline Louapre
11 months
RT @lazzarotto89: Thank you @ECTRIMS for the great opportunity to present my work on deep sulcal inflammation in MS #PET #MRI https://t.co/….
0
4
0
@clouapre
Céline Louapre
11 months
RT @DUFOUR_Jul: Thank you for the opportunity to present my PhD work about early energetic dysregulation in MS, during the @ECTRIMS 2024 co….
0
1
0
@clouapre
Céline Louapre
11 months
RT @bart_professor: Thouvenot (Fr) D-Lay MS study with vitamin D (100k IU/14d) in CIS. Showing 34% risk reduction of new disease activity v….
0
5
0
@clouapre
Céline Louapre
11 months
Great results of D-Lay MS trial in France coordinated by Pr Thouvenot from Nîmes University Hospital, presented at #ECTRIMS2024 @ECTRIMS Vit D reduced disease activity in early MS @FCRIN_network
Tweet media one
1
2
10
@clouapre
Céline Louapre
1 year
RT @InstitutCerveau: Retour en photos sur l'édition 2024 du tournoi international de #sémiologie neurologique pour les étudiant·es en médec….
0
2
0
@clouapre
Céline Louapre
1 year
0
0
1
@clouapre
Céline Louapre
1 year
Lancement de l’édition 2024 The move Europe!!! Le plus grand tournoi international de neurologie @InstitutCerveau @Sorbonne_Univ_ @APHP @HopPitieSalpe
Tweet media one
1
5
12
@clouapre
Céline Louapre
1 year
RT @FondationARSEP: 📣conférence #scléroseenplaques les espoirs de la recherche . Semaine du #cerveau !. 📅lundi 11 mars.⏰17h-19h15. - Célin….
0
7
0
@clouapre
Céline Louapre
2 years
RT @Brain1878: Butzkueven et al. report that daily oral vitamin D3 supplements did not delay the conversion of high-risk clinically isolate….
0
11
0
@clouapre
Céline Louapre
2 years
RT @FondationARSEP: 📣Identification de 5 symptômes annonciateurs d’une maladie inflammatoire auto-immune telle que la #scleroseenplaques. L….
0
6
0
@clouapre
Céline Louapre
2 years
Check out our new study on prodromal (but also early stage) symptoms in #MS : not that specific to MS! Congratulation to @guinebro and @thomas_nedelec from @AramisLabParis @SDurrleman at @InstitutCerveau for the hard work.
@AANmember
American Academy of Neurology
2 years
New Study Published in @GreenJournal: #Depression, Constipation, and Urinary Tract Infections May Precede #MS Diagnosis. #AANscience #Neurology
Tweet media one
0
6
16
@clouapre
Céline Louapre
2 years
L’etude BTKi avec evobrutinib est négative chez les patients avec SEP RR. Pas de différence par rapport au teriflunomide sur le risque de poussée. Evobrutinib Phase III | Merck
Tweet card summary image
merckgroup.com
Merck announced that its two Phase III EVOLUTION clinical trials of evobrutinib did not meet their primary endpoints.
0
2
6
@clouapre
Céline Louapre
2 years
RT @es_arman: 📢 New study: cost savings potential in treating Multiple Sclerosis (MS). If ocrelizumab was priced like its counterpart, rit….
0
6
0
@clouapre
Céline Louapre
2 years
Save the date pour les professionnels de santé: journée de formation sur la SEP progressive, organisée par la fédération neuro-SEP et les CRC SEP d'ile de France, le 28 mars 2024. Inscriptions: @ANAINFrance @FondationARSEP @SFNeurologie @FCRIN_network.
0
4
3